Teaching Construction Management Through Games Alone: A Detailed Investigation

by Long, G., Mawdesley, M., Scott, David
Published 2008

Promiscuous drugs compared to selective drugs (promiscuity can be a virtue)

by Mencher, Simon K, Wang, Long G
Published 2005

Mithramycin Targets Sp1 and The Androgen Receptor Transcription Level—Potential Therapeutic Role in Advanced Prostate Cancer

by Wang, Long G., Ferrari, Anna C.
Published 2006

Analysis and Example of International Use of Simulation Games in Multiple Roles for Teaching and Learning in Construction Management

by Mawdesley, M., Long, G., Al-jibouri, S., Scott, David, Gribble, Susan
Published 2008

Cellular and molecular toxicity of lead in bone.

by Pounds, J G, Long, G J, Rosen, J F
Published 1991

Are changes in glycaemic control associated with diabetes-specific quality of life and health status in screen-detected type 2 diabetes patients? Four-year follow up of the ADDITIO...

by Kuznetsov, L, Long, G H, Griffin, S J, Simmons, R K
Published 2015

Intra-patient heterogeneity of BRAF mutation status: fact or fiction?

by Menzies, A M, Wilmott, J S, Long, G V, Scolyer, R A
Published 2014

Revealing mechanisms underlying variation in malaria virulence: effective propagation and host control of uninfected red blood cell supply

by Metcalf, C. J. E., Long, G. H., Mideo, N., Forester, J. D., Bjørnstad, O. N., Graham, A. L.
Published 2012

Histological and Finite Element Analysis of Cell Death due to Irreversible Electroporation

by Long, G., Bakos, G., Shires, P. K., Gritter, L., Crissman, J. W., Harris, J. L., Clymer, J. W.
Published 2014

Change in cardio-protective medication and health-related quality of life after diagnosis of screen-detected diabetes: Results from the ADDITION-Cambridge cohort

by Black, J.A., Long, G.H., Sharp, S.J., Kuznetsov, L., Boothby, C.E., Griffin, S.J., Simmons, R.K.
Published 2015

AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma

by Hu, W, Jin, L, Jiang, C C, Long, G V, Scolyer, R A, Wu, Q, Zhang, X D, Mei, Y, Wu, M
Published 2013

BRAFV600E protein expression and outcome from BRAF inhibitor treatment in BRAFV600E metastatic melanoma

by Wilmott, J S, Menzies, A M, Haydu, L E, Capper, D, Preusser, M, Zhang, Y E, Thompson, J F, Kefford, R F, von Deimling, A, Scolyer, R A, Long, G V
Published 2013

Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study

by Long, G. V., Atkinson, V., Ascierto, P. A., Robert, C., Hassel, J. C., Rutkowski, P., Savage, K. J., Taylor, F., Coon, C., Gilloteau, I., Dastani, H. B., Waxman, I. M., Abernethy, A. P.
Published 2016

Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy

by Bowyer, S, Prithviraj, P, Lorigan, P, Larkin, J, McArthur, G, Atkinson, V, Millward, M, Khou, M, Diem, S, Ramanujam, S, Kong, B, Liniker, E, Guminski, A, Parente, P, Andrews, M C, Parakh, S, Cebon, J, Long, G V, Carlino, M S, Klein, O
Published 2016

Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma

by Carlino, M S, Haydu, L E, Kakavand, H, Menzies, A M, Hamilton, A L, Yu, B, Ng, C C, Cooper, W A, Thompson, J F, Kefford, R F, O'Toole, S A, Scolyer, R A, Long, G V
Published 2014